1. Home
  2. SAGE vs SIGA Comparison

SAGE vs SIGA Comparison

Compare SAGE & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • SIGA
  • Stock Information
  • Founded
  • SAGE 2010
  • SIGA 1995
  • Country
  • SAGE United States
  • SIGA United States
  • Employees
  • SAGE N/A
  • SIGA N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • SIGA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SAGE Health Care
  • SIGA Health Care
  • Exchange
  • SAGE Nasdaq
  • SIGA Nasdaq
  • Market Cap
  • SAGE 415.0M
  • SIGA N/A
  • IPO Year
  • SAGE 2014
  • SIGA 1997
  • Fundamental
  • Price
  • SAGE $6.71
  • SIGA $5.44
  • Analyst Decision
  • SAGE Hold
  • SIGA
  • Analyst Count
  • SAGE 19
  • SIGA 0
  • Target Price
  • SAGE $9.88
  • SIGA N/A
  • AVG Volume (30 Days)
  • SAGE 934.8K
  • SIGA 579.6K
  • Earning Date
  • SAGE 04-29-2025
  • SIGA 05-08-2025
  • Dividend Yield
  • SAGE N/A
  • SIGA 11.03%
  • EPS Growth
  • SAGE N/A
  • SIGA N/A
  • EPS
  • SAGE N/A
  • SIGA 0.82
  • Revenue
  • SAGE $47,404,000.00
  • SIGA $138,719,350.00
  • Revenue This Year
  • SAGE $100.64
  • SIGA N/A
  • Revenue Next Year
  • SAGE $70.19
  • SIGA $95.35
  • P/E Ratio
  • SAGE N/A
  • SIGA $6.40
  • Revenue Growth
  • SAGE N/A
  • SIGA N/A
  • 52 Week Low
  • SAGE $4.62
  • SIGA $4.95
  • 52 Week High
  • SAGE $14.56
  • SIGA $12.83
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 35.06
  • SIGA 42.98
  • Support Level
  • SAGE $7.23
  • SIGA $5.21
  • Resistance Level
  • SAGE $7.63
  • SIGA $5.64
  • Average True Range (ATR)
  • SAGE 0.29
  • SIGA 0.21
  • MACD
  • SAGE -0.09
  • SIGA -0.09
  • Stochastic Oscillator
  • SAGE 0.38
  • SIGA 16.43

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Share on Social Networks: